HRES 161

Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.

Congress: 113 (2013–2015, Ended)
Chamber: House
Policy Area: Health
Introduced: Apr 15, 2013
Current Status: Referred to the Subcommittee on Health.
Latest Action: Referred to the Subcommittee on Health. (Apr 19, 2013)
Official Text: https://www.congress.gov/bill/113th-congress/house-resolution/161

Sponsor

Name: Rep. Rogers, Harold [R-KY-5]
Party: Republican • **State:** KY • **Chamber:** House

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Aderholt, Robert B. [R-AL-4]	R · AL		Apr 15, 2013
Rep. Grimm, Michael G. [R-NY-11]	R · NY		Apr 15, 2013
Rep. Keating, William R. [D-MA-9]	D · MA		Apr 15, 2013
Rep. Lynch, Stephen F. [D-MA-8]	D · MA		Apr 15, 2013
Rep. Rahall, Nick J., II [D-WV-3]	D · WV		Apr 15, 2013
Rep. Tierney, John F. [D-MA-6]	D · MA		Apr 15, 2013
Rep. Wolf, Frank R. [R-VA-10]	R · VA		Apr 15, 2013

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Apr 19, 2013

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
113 SRES 97	Related bill	**Apr 15, 2013:** Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)

Summary (as of Apr 15, 2013)

Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.

Actions Timeline

- **Apr 19, 2013:** Referred to the Subcommittee on Health.
- **Apr 15, 2013:** Introduced in House
- **Apr 15, 2013:** Referred to the House Committee on Energy and Commerce.